http://www.jacionline.org/article/S0091-6749%2812%2902692-9/fulltext (http://www.jacionline.org/article/S0091-6749%2812%2902692-9/fulltext)
The upshot:
Quote
Meticulous care is taken by our omalizumab administration clinic to ensure optimal safety based on the emphasized warnings of anaphylaxis. Data collected in this analysis observed no cases of anaphylaxis in the treatment of over 200 patients, during a period of 14 years, who combined received 20,000 injections of omalizumab.
This is great news, since the FDA has estimated an anaphylaxis rate of about 0.2% with Xolair-- a finding which
may be too high, it seems.